Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



Estimation of Plasma Glucose and Creatinine Level in Alloxan-induced Diabetic Wistar Rats treated with Metformin and Thiazolidinediones

Ojo Patience Oluwatomilayo, Akinola Busayo Oluwole.




Abstract
Cited by 1 Articles

Introduction: Diabetes increases the risk of developing neuropathy. In this study, we estimate the effect of Metformin, rosiglitazone, and pioglitazone on the body weight, blood glucose and creatinine level of alloxan-induced diabetic rats.
Materials and Method: Alloxan (150 mg/kg) was used to induce hyperglycemia in fasted rats. Hyperglycaemia was treated with metformin, 150 mg/kg/d; pioglitazone, 3 mg/kg/d; and rosiglitazone, 10 mg/kg/d). The anti-diabetic drugs were administered orally for 28 days. The kidneys were removed when the animals were sacrificed plasma and kidney creatinine level was measured.
Results: There was the reduction in weight of diabetic rats and those administered with metformin while there was an increase in weight of rats administered with rosiglitazone and pioglitazone. There is also reduction in blood glucose level of all treated rats compared with the diabetes control. The effects of creatinine on muscle metabolism generation and serum are insignificant at P≤0.05.
Conclusion: This experiment suggests that short-term diabetes does not have an effect on plasma creatinine level and muscle metabolism of alloxan-induced diabetic rats.

Key words: Plasma glucose, Creatinine, Metformin, Thiazolidinediones






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.